This study examined whether hydromethylthionine (a tau aggregation inhibitor related to methylene blue) could restore glutamate release deficits in tau transgenic mice, finding that the compound successfully rescued synaptosomal glutamate release impairments associated with tau pathology. The research demonstrates a mechanistic link between tau aggregation and synaptic glutamate dysfunction in a mouse model of tauopathy. *Evidence level: Animal model* (Note: The source listed this as “Human Clinical,” but the actual study design employed tau transgenic mice, making this an animal model investigation).